**Core tip:** Endoscopic and histopathological findings are not always certain, thus potentially leading to inaccurate diagnoses and inappropriate therapeutics. The use of confocal laser endomicroscopy has a significant clinical impact on the diagnosis and treatment of patients with uncertain diagnoses.

INTRODUCTION
============

Conventional histology is the gold standard procedure in evaluating lesions in the gastrointestinal tract. However, endoscopic and histological findings are sometimes poorly correlated, thus hindering accurate diagnosis and subsequent clinical management\[[@B1]-[@B5]\]. The probability of sampling error has been found to be 20%-30% and is affected by several factors, such as inadequate macroscopic interpretation and minimal biopsy acquisition\[[@B6]\].

Confocal laser endomicroscopy (CLE) is a technique that is used *in vivo* during endoscopy to evaluate the mucosal epithelium of the gastrointestinal tract, the bile duct and pancreatic cysts\[[@B5],[@B7]\]. Furthermore, it provides dynamic information including blood flow and contrast up-take\[[@B8]\].

Multiple studies have shown that CLE has a diagnostic accuracy above 90% when standardized parameters are used to evaluate specific lesion features\[[@B9]-[@B17]\]. However, there is minimal information in the literature regarding the influence of CLE on the evaluation and management of patients with GI lesions of uncertain diagnosis. The aim of this study was to evaluate the clinical impact of CLE in this group of patients.

MATERIALS AND METHODS
=====================

Study design
------------

This study was an observational, analytical, retrospective, cross-sectional single-center study. Prospective data from November 2013 to September 2015 were collected at the Ecuadorian Institute of Digestive Diseases (IECED) Omni Hospital Academic Tertiary Care Center, Guayaquil, Ecuador. The study protocol was approved by the Institutional Ethical and Review Board and conducted according to the guidelines in the declaration of Helsinki.

Demographic data, indications, previous diagnostic findings, CLE findings, clinical management and histological results are described. Records from previous endoscopies \[*i.e*., upper endoscopy (UE), colonoscopy with high definition magnification and digital chromoendoscopy, endoscopic retrograde cholangiopancreatography (ERCP) with brushing sample and endoscopic ultrasound (EUS)\], computed tomography (CT), magnetic resonance imaging (MRI) cholangiopancreatography and tests for tumor markers were analyzed.

Population selection
--------------------

**Inclusion criteria:** Patients who underwent CLE (Cellvizio^®^, Mauna Kea Technology, France) as a result of an uncertain diagnosis (an absence of correlation between endoscopic and histological findings) in gastrointestinal diseases, including neoplastic (N) or non-neoplastic (NN) lesions (Table [1](#T1){ref-type="table"}). Patients ≥ 18 years old; Patients who agreed to participate; Patients with no previous p-CLE.

###### 

Baseline characteristics *n* (%)

                                 **Biopsy/surgical specimen diagnosis**   ***P* value**                  
  ------------------------------ ---------------------------------------- --------------- -------------- ----------
  Sex (female)                   74 (51.4)                                19 (46.3)       55 (53.4)      0.445
  Age, yr, mean ± SD             51.33 ± 16.5                             56.73 ± 17.1    49.19 ± 15.8   0.014
  Initial endoscopy indication                                                                           \< 0.001
  Suspected tumor                70 (48.6)                                32 (78.0)       38 (36.9)      
  Other                          74 (51.4)                                9 (22.0)        65 (63.1)      
  Location                                                                                               0.187
  Vater ampulla                  2 (1.4)                                  1 (2.4)         1 (1.0)        
  Colon                          14 (9.7)                                 6 (14.6)        8 (7.8)        
  Duodenum                       4 (2.8)                                  1 (2.4)         3 (2.9)        
  Esophagus                      24 (16.7)                                8 (19.5)        16 (15.5)      
  Stomach                        59 (41.0)                                10 (24.4)       49 (47.6)      
  Ileum                          1 (0.7)                                  0 (0.0)         1 (1.0)        
  Pancreas                       8 (5.6)                                  1 (2.4)         7 (6.8)        
  Rectum                         3 (2.1)                                  1 (2.4)         2 (1.9)        
  Bile duct                      29 (20.1)                                13 (31.7)       16 (15.5)      

SD: Standard deviation.

**Exclusion criteria:** Pregnant patients and patients with allergies and/or contraindication to fluorescein.

Endoscopy and CLE procedures
----------------------------

All participants underwent CLE according to the standard protocol. Sedation was accomplished with propofol in UE and colonoscopy and general anesthesia in ERCP and EUS. In UE and colonoscopy, the CLE was performed with Gastroflex^®^ and Coloflex^®^ probes (Cellvizio^®^, Mauna Kea Technology, France) through the working channel of a standard video-endoscope. In ERCP procedures, CLE was performed through cholangioscopy (SpyGlass^®^ system, Boston Scientific^®^), and in EUS, CLE was performed through a 19G needle (Expect^®^ needle, Boston Scientific) with Cholangioflex^®^ and AQ-flex^®^ probes (Cellvizio^®^, Mauna Kea Technology, France).

After the GI mucosa was inspected, the areas with suspected pathology were further examined. The probe was carefully advanced to the mucosa, and *in vivo* microscopy images were scanned at 1000 × magnification by using CLE. These video images were transmitted in a real-time onto a screen situated next to the endoscopy monitor. For tissue contrast, 5 mL of 10% fluorescein was injected in all patients.

All lesions were analyzed in real-time after an endoscopic assessment. Micrographs and videos obtained during CLE were stored for further examination. The images were interpreted according to methods previously published in esophageal\[[@B18],[@B19]\], gastric\[[@B14],[@B20],[@B21]\] and colonic\[[@B22]-[@B24]\] lesions. The Miami\[[@B25],[@B26]\], Paris\[[@B13]\], and CONTACT\[[@B11]\] study criteria for using CLE were used in bilio-pancreatic tract and cystic pancreatic lesions.

Definitions
-----------

An uncertain diagnosis in a case of gastrointestinal lesions was defined as a lack of correlation between a histological report and findings on initial endoscopy (*e.g*., UE, colonoscopy, ERCP, EUS). Neoplastic (N) lesions included dysplasia, adenomas and carcinomas that were located at any level of the GI tract, pancreas or biliary duct. Any other lesion was defined as a non-neoplastic (NN) lesion (Figures [1](#F1){ref-type="fig"} and [2](#F2){ref-type="fig"}).

![Colonic polyp. A: A sigmoid flat polyp was viewed using digital chromoendoscopy with high definition by i-scan, which revealed a pit pattern suggestive of a hyperplastic lesion in a patient with cirrhosis and important coagulation disorders; B: CLE showing dysplasia (image optimized by using a green-white image color palette in Cellvizio^®^ viewer software); C: A histological analysis of the specimen confirmed the dysplasia. CLE: Confocal laser endomicroscopy.](WJGE-9-389-g001){#F1}

![Undetermined stenosis of the biliary tract. A: ERCP was performed in a patient with undetermined stenosis who was cytobrush-negative for malignancy; B: Spyglass cholangioscopy showing a reddish area that was not suspected of malignancy; C: CLE showing dark clumps that were suspected of malignancy (image optimized using the "black-red-yellow" image color palette in Cellvizio^®^ viewer software); D: The histological results of a target biopsy confirmed a diagnosis of cholangiocarcinoma. CLE: Confocal laser endomicroscopy; ERCP: Endoscopic retrograde cholangiopancreatography.](WJGE-9-389-g002){#F2}

We defined a "change in management" resulting from CLE in cases of uncertain diagnosis when the results of CLE changed the management strategy that was initially based on the original biopsy or when no further diagnostic methods were used.

Statistical analysis
--------------------

Baseline characteristics, including demographic data, indications, CLE findings, histological results and changes in management, were described as percentages and ranges or means and standard deviations, as appropriate. The overall diagnostic accuracy of CLE in an N-lesion was determined by comparing the CLE findings to the final post-CLE histopathological report (*e.g*., biopsy or surgical specimen). The following measurements were used for this purpose: Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), simple percentage agreement (observed agreement) and inter-rater agreement (Cohen's Kappa). Cohen's Kappa was interpreted by using Landis and Koch-Kappa's Benchmark Scale. Changes in management and redirected biopsy samples were described as percentages. The characteristics of N-lesions and NN-lesions groups were compared using Student's *t*-test for continuing variables and χ^2^ and Fisher's test for categorical variables. A *P* value \< 0.05 was considered to be statistically significant. The statistical methodology used in this study was reviewed by the IECED institutional Biostatistician. Statistical calculations were performed in SPSS software suite v.22.

RESULTS
=======

A total of 144 patients were included. The mean age of the patients was 51.33 years old (range 18-86), and 51.4% (74/144) were female. There were 41/ 144 N-lesions, including 13 bile duct, 10 gastric, 8 esophageal, 6 colonic, 1 duodenal, 1 rectal, 1 ampulloma and 1 pancreatic lesion (Table [1](#T1){ref-type="table"}). The findings included Barrett's esophagus with or without dysplasia, adenocarcinomas and mucosal inflammation in different segments of the digestive tract, gastric metaplasia and dysplasia, carcinoid tumors, ampulloma, mucinous and serous pancreatic cysts, pseudocysts, adenoma and adenocarcinoma of the biliary tract and inflammation related to parasites.

The sensitivity, specificity, PPV and NPV for detecting N-lesions between CLE and target biopsies or surgical specimens were 85.37%, 87.38%, 72.92% and 93.75%, respectively. The observed agreement was 86.81%, and Cohen's Kappa value was 69.20%, thus indicating good agreement (Table [2](#T2){ref-type="table"}). Changes in management were noted in 78/144 (54.2) cases (Table [3](#T3){ref-type="table"}). These changes resulted from the improved ability of CLE to acquire targeted biopsies, which avoided the need for further diagnostic methods.

###### 

Confocal laser endomicroscopy overall diagnostic accuracy with either confocal laser endomicroscopy target biopsy or surgical specimens as the Gold Standard *n* (%)

                                    **Biopsy/surgical specimen diagnosis**   ***P* value**                          
  --------------------------------- ---------------------------------------- --------------- ---------------------- ----------
  CLE diagnosis                                                                                                     \< 0.001
  Neoplastic lesion                 48 (33.3)                                35 (85.4)       13 (12.6)              
  Non-Neoplastic lesion             96 (66.7)                                6 (14.6)        90 (87.4)              
  CLE overall diagnostic accuracy                                                                                   
  Sensitivity, *n*/T (%; 95%CI)                                              35/41           (85.37; 70.83-94.43)   
  Specificity, *n*/T (%; 95%CI)                                              90/103          (87.38; 79.38-93.11)   
  PPV, *n*/T (%; 95%CI)                                                      35/48           (72.92; 61.46-81.97)   
  NPV, *n*/T (%; 95%CI)                                                      90/96           (93.75; 87.71-96.93)   
  Observed agreement, *n*/T (%)                                              125/144         -86.81                 
  Cohen's Kappa, % (95%CI)                                                   69.2            (56.50-81.90)          

PPV: Positive predictive value; NPV: Negative predictive value; CI: Confidence interval; CLE: Confocal laser endomicroscopy.

###### 

Patients with changes in management following biopsy/surgical specimen diagnosis, listed according to organ *n* (%)

                  **Biopsy/surgical specimen diagnosis**   ***P* value**               
  --------------- ---------------------------------------- --------------- ----------- -------
  Location                                                                             0.707
  Vater ampulla   1 (1.3)                                  1 (3.3)         0           
  Colon           9 (11.5)                                 4 (13.3)        5 (10.4)    
  Duodenum        4 (5.1)                                  1 (3.3)         3 (6.3)     
  Esophagus       10 (12.8)                                5 (16.7)        5 (10.4)    
  Stomach         17 (21.8)                                5 (16.7)        12 (25)     
  Ileum           1 (1.3)                                  0               1 (2.1)     
  Pancreas        6 (7.7)                                  1 (3.3)         5 (10.4)    
  Rectum          3 (3.8)                                  1 (3.3)         2 (4.2)     
  Bile duct       27 (34.6)                                12 (40)         15 (31.3)   

DISCUSSION
==========

CLE is an imaging method that has demonstrated substantial benefit for diagnosing GI tract, bile duct and pancreatic lesions. Several previous reports have supported CLE's efficacy by showing CLE and histological findings are well correlated\[[@B15]-[@B17]\]. Recent studies\[[@B11],[@B18]\] have demonstrated that CLE has high accuracy in differentiating benign from malignant lesions in bile duct and pancreas pathology (mean accuracy, 81%)\[[@B21]\], malignant gastric lesions (94%-96%)\[[@B20]\] and polyps (82%)\[[@B22]\]. In addition, the American Society for Gastrointestinal Endoscopy has reported that CLE has at least 90% sensitivity and 98% NPV when it is used to detect Barrett's esophagus-associated dysplasia\[[@B18]\]. The Miami classification criteria for bile duct lesions have been demonstrated to have a higher accuracy when they are used to diagnose malignant strictures rather than biopsy samples (81% *vs* 75%, respectively)\[[@B12]\]. However, these criteria have some limitations when they are used to differentiate inflammatory from malignant strictures, thus leading to false positives. On the basis of this finding, Caillol et al\[[@B13]\] have developed the Paris Classification, which has increased sensitivity and specificity in characterizing indeterminate bile duct strictures\[[@B13],[@B27]\]. Additionally, in colonoscopy, CLE has been demonstrated to be very useful. Neumann et al\[[@B23],[@B24]\] have found that CLE, when used in inflammatory bowel disease (IBD) surveillance, is a simple technique that facilitates the accurate and early detection of related lesions.

Our study focused on the clinical impact and management changes resulting from the use of CLE to evaluate GI (upper and lower) lesions, including bile duct pathology and pancreatic cysts, in a subgroup of patients with uncertain diagnoses due to non-conclusive previous tests.

CLE was found to have a high accuracy in detecting neoplastic bilio-pancreatic lesions, which accounted for 80% of all lesions found in the bile ducts and pancreas. In 54% of such cases, the use of CLE resulted in a change in the diagnostic and therapeutic approach. However, 71% of all lesions in patients with an inconclusive diagnosis were NN benign lesions, and CLE resulted in an observed agreement, PPV and NPV of 86%, 72% and 93%, respectively. These results were similar to those reported in previous publications that have explored lesions in the upper and lower portions of the gastrointestinal tract\[[@B1],[@B22]-[@B30]\].

The main advantages of using CLE include its ability to differentiate *in vivo* lesions and guide targeted biopsies, thereby avoiding the potential complications associated with endoscopic mucosal resections (*e.g*., perforation or bleeding). Additionally, using CLE prevents a need for further unnecessary invasive and noninvasive diagnostic methods (*e.g*., repeated endoscopy, ERCP, EUS, or other imaging modalities, such as CT and MRI), thus decreasing patient risk and economic burden associated with such procedures. However, our study has limitations, including its single-center retrospective design and lack of randomization.

Conclusion
----------

The results of this study suggest that CLE is a valuable diagnostic tool for patients with an uncertain diagnosis (neoplastic or non-neoplastic). CLE can be used to perform real-time evaluation of the GI mucosa, thus allowing endoscopists to target biopsies and having a significant clinical impact when it is used to improve and modify diagnoses and treatment strategies.

COMMENTS
========

Background
----------

Confocal laser endomicroscopy (CLE) is a technique that can be used *in vivo* during endoscopy to evaluate the mucosal epithelium of the gastrointestinal tract, the bile duct and pancreatic cysts.

Research frontiers
------------------

The authors evaluated the clinical impact of CLE in patients with an uncertain diagnosis in gastrointestinal lesions.

Innovations and breakthroughs
-----------------------------

The observed agreement was 86.81% and had a Cohen's Kappa value of 69.20%, thus indicating good agreement. Changes in management were noted in 78/144 (54.2) cases and were associated with the improved acquisition of targeted biopsies, thus avoiding the need for further diagnostic tests.

Applications
------------

CLE is a new diagnostic tool that can be used in patients with uncertain diagnosis, in whom it has a significant clinical impact on diagnosis and treatment.

Terminology
-----------

Confocal laser endomicroscopy; *in vivo* microscopy.

Peer-review
-----------

Overall the paper is interesting and points out discrepancy between endoscopic and histopathologic findings.
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